Cargando…
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune...
Autores principales: | Chemaitelly, Hiam, Ayoub, Houssein H, AlMukdad, Sawsan, Faust, Jeremy S, Tang, Patrick, Coyle, Peter, Yassine, Hadi M, Al Thani, Asmaa A, Al-Khatib, Hebah A, Hasan, Mohammad R, Al-Kanaani, Zaina, Al-Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar H, Latif, Ali N, Shaik, Riyazuddin M, Abdul-Rahim, Hanan F, Nasrallah, Gheyath K, Al-Kuwari, Mohamed G, Butt, Adeel A, Al-Romaihi, Hamad E, Al-Thani, Mohamed H, Al-Khal, Abdullatif, Bertollini, Roberto, Abu-Raddad, Laith J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481416/ https://www.ncbi.nlm.nih.gov/pubmed/37555656 http://dx.doi.org/10.1093/jtm/taad106 |
Ejemplares similares
-
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2021) -
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022) -
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
por: Abu-Raddad, Laith J, et al.
Publicado: (2021) -
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022) -
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2022)